- Home
- BDRX vs GTBP Comparison
BDRX vs GTBP Comparison
Compare BDRX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- GTBP
- Stock Information
- Founded
- BDRX 2000
- GTBP 1965
- Country
- BDRX United Kingdom
- GTBP United States
- Employees
- BDRX N/A
- GTBP N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- GTBP Health Care
- Exchange
- BDRX Nasdaq
- GTBP Nasdaq
- Market Cap
- BDRX 5.8M
- GTBP 5.5M
- IPO Year
- BDRX N/A
- GTBP N/A
- Fundamental
- Price
- BDRX $0.87
- GTBP $2.26
- Analyst Decision
- BDRX
- GTBP Strong Buy
- Analyst Count
- BDRX 0
- GTBP 1
- Target Price
- BDRX N/A
- GTBP $11.00
- AVG Volume (30 Days)
- BDRX 3.1M
- GTBP 111.6K
- Earning Date
- BDRX 04-11-2025
- GTBP 08-13-2025
- Dividend Yield
- BDRX N/A
- GTBP N/A
- EPS Growth
- BDRX N/A
- GTBP N/A
- EPS
- BDRX N/A
- GTBP N/A
- Revenue
- BDRX N/A
- GTBP N/A
- Revenue This Year
- BDRX N/A
- GTBP N/A
- Revenue Next Year
- BDRX N/A
- GTBP N/A
- P/E Ratio
- BDRX N/A
- GTBP N/A
- Revenue Growth
- BDRX N/A
- GTBP N/A
- 52 Week Low
- BDRX $0.78
- GTBP $1.72
- 52 Week High
- BDRX $41.50
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- BDRX 38.67
- GTBP 38.82
- Support Level
- BDRX $0.85
- GTBP $1.91
- Resistance Level
- BDRX $0.92
- GTBP $3.73
- Average True Range (ATR)
- BDRX 0.06
- GTBP 0.33
- MACD
- BDRX 0.01
- GTBP -0.16
- Stochastic Oscillator
- BDRX 32.73
- GTBP 19.59
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.